After mulling over the idea for several years, the pharma giant, Pfizer, is set to protect its patients and promote its new drug ‘Panzyga’, for the rare disorder, chronic inflammatory demyelinating polyneuropathy (CIPD), through the warranty programme. Last year, Pfizer took this initiative for its then-newly approved drug Xalkori for lung cancer. The pharma behemoth says that they will offer a refund to the patient and their insurer for four treatments of the drug in case the patient’s healthcare provider ceases its use for ‘clinical reasons’. The programme of Panzyga is available only to individuals who are covered by commercial insurance or pay cash, unlike Xalkori, whose warranty extended to the government assistance and Medicare programme.
Read More from FiercePharma
